Wolfe Research initiated coverage on ORIC Pharmaceuticals
$ORIC
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research initiated coverage of ORIC Pharmaceuticals with a rating of Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2026 | $22.00 | Overweight | Piper Sandler |
| 11/20/2025 | $25.00 | Outperform | Evercore ISI |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 9/4/2025 | $18.00 | Buy | Guggenheim |
| 7/8/2025 | $15.00 | Buy | Ladenburg Thalmann |
| 10/31/2024 | $20.00 | Overweight | Wells Fargo |
| 9/6/2024 | $20.00 | Buy | Stifel |
| 2/23/2024 | Overweight | Cantor Fitzgerald |
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:45 a.m. PT. A live webcast of the company presentation will be available through the investor section of the company's website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceutica
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR
Piper Sandler initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $22.00
Evercore ISI initiated coverage of ORIC Pharmaceuticals with a rating of Outperform and set a new price target of $25.00
Wolfe Research initiated coverage of ORIC Pharmaceuticals with a rating of Peer Perform
144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiat
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC pati
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L EGFR PACC patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 04, 2025 (GLOBE NE
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)